
Daily Derm Times: August 19, 2025
Key Takeaways
- Innovative topical therapies are enhancing psoriasis and atopic dermatitis management, improving patient outcomes and simplifying treatment for diverse skin types.
- Jean Tang, MD, PhD, emphasizes the significance of pz-cel, which uses patient-derived skin cells to treat epidermolysis bullosa by correcting the COL7A1 mutation.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our
From Scalp to Skin: Modernizing Psoriasis Treatment With Versatile Topical Solutions
Explore the latest advancements in psoriasis treatment with innovative topical therapies, enhancing patient outcomes and simplifying management for diverse skin types.
Jean Tang, MD, PhD, Reflects on FDA Approval of pz-cel for EB
Jean Tang, MD, PhD, professor of dermatology at Stanford University and general dermatologist at Stanford Medicine Children’s Health, highlighted how the therapy harnesses a patient’s own skin cells, corrects the COL7A1 mutation ex vivo, and expands them into keratinocyte sheets that are surgically applied to chronic wounds.
Anthony Rossi, MD, FAAD, FACMS, Discusses Science, Simplicity, and the Skin
Dr. Rossi DERM MD blends dermatologic science with K-beauty aesthetics for effective, evidence-based solutions.
Leaving Home Sparks New Challenges in Atopic Dermatitis Care
Expanded prescribing rights for pharmacists could ease treatment delays and improve access for AD patients.
Navigating a New Era of AD Treatment Options
Explore expert insights from Adam Friedman, MD, FAAD, on emerging topical treatments for atopic dermatitis, featuring real-world cases and practical strategies for improving care and access.
How New Topical Therapies Are Transforming Atopic Dermatitis Care
At the Elevate-Derm Summer 2025 meeting, Walter Liszewski, MD, discussed how new topical therapies, particularly JAK inhibitors, are transforming AD care with rapid itch relief, effectiveness in complex cases, and patient-friendly formulations for sensitive areas.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















